Brunde
Broady

Director

After graduating from Yale with an MBA in 1994, Brunde became a partner in a family controlled venture firm. The firm maintains a long-term investment horizon, and it has funded several start-ups from its inception to upwards of $150 million-dollar valuation.

The firm’s worldwide portfolio has business interests in England, Germany, and China in nutraceuticals, software, technology, and, most recently, biopharma. Principals amongst the biopharma portfolio companies have long standing relationships with individuals at the NIH, FDA, academic Institutions, as well as Biopharm VCs.

LEARN MORE